



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Miri Seiberg et al.

Confirmation No.: 5255

Serial No.

09/206,249

Art Unit: 1655

Filed

December 7, 1998

Examiner: Michael V. Meller

For

Methods for Regulating Phagocytosis and ICAM-1 Expression

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

August 21, 2006			
(Date of Deposit)			
Andrea L. Colby, Reg. No. 30,194			
(Name of applicant, assignee, or Registered Representative)			
/Andrea L. Colby/			
(Signature)			
August 21, 2006			
August 21, 2000			
(Data of Cignoture)			

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement						
is being filed either within three months of the filing date of the above-identified						
national application (other than a continued prosecution application under §1.53(d)),						
within three months of the date of entry into the national stage of the above identified						
application as set forth in §1.491, or before the mailing date of a first Office Action on						
the merits of the above-identified application, or before the mailing date of a first Office						
Action after the filing of a request for continued examination under §1.114, no						
additional fee is required.						
In accordance with §1.97(c), this Information Disclosure Statement is						
being filed after the period set forth in §1.97(b) above but before the mailing date of						
either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action						
that otherwise closes prosecution and that it is accompanied by one of:						
Statement in Accordance with §1.97(e) (attached); or						
Please charge Deposit Account No. 10-0750 the fee of \$180.00						
as set forth in §1.17(p).						
In accordance with §1.97(d), this Information Disclosure Statement is						
being filed after the mailing date of either a Final Action under §1.113 or a Notice of						
Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s)						
hereby petition(s) for consideration of this Information Disclosure Statement. Included						
are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00						
as set forth in §1.17(p).						
Copies of only foreign patent documents and non-patent literature are						
enclosed in accordance with 37 CFR 1.98 (a)(2).						
There are no listed references which are not in the English language.						
\cdot						
The relevance of those listed references which are not in the English						
language is as follows:						

English language abstracts are p	rovided for the foreign patent documents listed				
on the form SB/08/A.					
Attached are copies of sea	Attached are copies of search report(s) from corresponding patent				
application(s), which are listed on the at	tached Submission Under MPEP 609 D.				
Attached are the following	non-published pending patent applications				
which may be deemed relevant, which a	are listed on the attached Submission Under				
MPEP 609 D.					
Please charge any deficiency or	credit any overpayment to Deposit Account				
No. 10-0750/JBP438/ALC. This form is	submitted in triplicate.				
	Respectfully submitted,				
	/Andrea L. Colby/				
	Andrea L. Colby				
	Reg. No. 30,194				
Johnson & Johnson	Attorney for Applicants				
One Johnson & Johnson Plaza					
New Brunswick, NJ 08933-7003					
(732) 524-2792					
DATED: August 21, 2006					

AUG 2 3 2006 0

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

stitute for form AMSA/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

to respond to a consecution undiring borr divises it displays a valid office control mander.				
Confirmation Number	5255			
Application Number	09/206,249			
Filing Date	12/07/1998			
First Named Inventor	Miri Seiberg			
Group Art Unit	1655			
Examiner Name	Michael V. Meller			
Attorney Docket Number	JBP0438US			

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Kind Code Exam Cite where relevant passages or of Cited Document of Cited Document Initials Number (if known) relevant figures appear No.1 mm-dd-yyyy 2004/0063593 **A1** Wu et al. 04-01-2004

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Publication of Lines, where relevant Name of Patentee or Exam Cite Cited Document passages or relevant Applicant of Cited Document Initials figures appear Office³ Number⁴ KindCode5 No.1 mm-dd-yyyy Li CN 1146876 Α 04-09-1997 English Abst. 1166960 Α 12-10-1997 English Abst. Jin Α DE 19818849 Med-Beauty AG 10-29-1998 English Abst. EP Α 06-05-2002 1210946 Neutrogena Corp.

Exam Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²

Examiner /	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

